<DOC>
	<DOCNO>NCT01719614</DOCNO>
	<brief_summary>The purpose study evaluate effect steady-state ( constant concentration medication blood ) rilpivirine pharmacokinetics ( single dose metformin absorb body , distribute within body , remove body ) single dose metformin , time , healthy adult participant .</brief_summary>
	<brief_title>A Study Explore Pharmacokinetic Interaction Between Rilpivirine Metformin Healthy Participants</brief_title>
	<detailed_description>This phase I , open-label ( people know identity intervention ) sequential study ( study medication give sequence ) healthy participant , investigate pharmacokinetic interaction steady-state rilpivirine single dose metformin . The study consist 3 phase include , screen phase ( 28 day enrollment ) , treatment phase ( 19 day ) , follow-up phase ( 7 day last intake study medication ) . All participant receive study medication two session fix , sequential order session 1 ( single dose metformin Day 1 ) follow washout period ( period treatment receive ) 4 day session 2 ( rilpivirine Day 5 Day 17 single dose metformin Day 15 ) . The duration study approximately 54 day . Safety evaluation include adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination ( include skin examination ) monitor throughout study .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<criteria>Participants healthy basis physical examination , medical history , vital sign , electrocardiogram , result blood biochemistry hematology test urinalysis perform screen Participant must Body Mass Index 18.5 30.0 kg/m2 Male participant agree protocoldefined use effective contraception woman must postmenopausal surgically sterile Female participant must negative pregnancy test screen Participants must nonsmoking least 3 month prior screen A positive Human immunodeficiency virus ( HIV ) 1 HIV2 test Hepatitis A , B C infection screen Currently active clinically significant gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , endocrine , renal , hepatic , respiratory , inflammatory infectious disease history clinically significant skin disease Any history tuberculosis , ocular herpes , uveitis Have previously participate one study etravirine TMC120 ( dapivirine ) and/or rilpivirine Participants abnormal laboratory value screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Healthy participant</keyword>
	<keyword>Rilpivirine</keyword>
	<keyword>Metformin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>